
Valneva’s Breakthrough: Canada Approves World’s First Chikungunya Vaccine
Valneva SE has achieved a historic milestone with Health Canada’s approval of the world’s first chikungunya vaccine. Following its successful launch in the U.S. and pending European authorization, this decision underscores IXCHIQ®’s pivotal role in global healthcare strategy. Chikungunya, a mosquito-borne virus causing severe joint pain and fever, poses a significant public health threat with…